A prospective study of G-CSF-primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: A Pediatric Blood and Marrow Transplant Consortium (PBMTC) study

Haydar Frangoul, Eneida Nemecek, Dean Billheimer, Michael A. Pulsipher, Shakila Khan, Ann Woolfrey, Becky Manes, Catherine Cole, Mark C. Walters, Mouhab Ayas, Yaddanapudi Ravindranath, John E. Levine, Stephan A. Grupp

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

A prospective multicenter trial was conducted to evaluate the safety and feasibility of granulocyte colony-stimulating factor (G-CSF)-primed bone marrow (G-BM) in children receiving allogeneic bone marrow transplantation (BMT). A total of 42 children with a median age of 9.8 years (range, 0.8-17 years) were enrolled. Donors with median age of 9.2 years (range, 1.1-22 years) received 5 μg/kg per day of subcutaneous G-CSF for 5 consecutive days. BM was harvested on the fifth day. No donor experienced complications related to G-CSF administration or marrow harvest. Median nucleated (NC) and CD34 cells infused was 6.7 × 108/kg (range, 2.4-18.5 × 108/kg) and 7.4 × 106/kg (range, 2-27.6 × 106/kg), respectively. Neutrophil and platelet engraftment was at a median of 19 days (range, 13-28 days) and 20 days (range, 9-44 days), respectively. A total of 13 (32%) patients developed grade 2 graft-versus-host disease (GVHD), and 5 (13%) of 40 evaluable patients developed chronic GVHD (3 limited and 2 extensive). Higher cell dose was not associated with increased risk of acute or chronic GVHD. Overall survival and event-free survival at 2 years were 81% and 69%, respectively. Collection of G-BM from pediatric donors is safe, and can result in high NC and CD34 cell doses that facilitate engraftment after myeloablative BMT without a discernable increase in the risk of GVHD.

Original languageEnglish (US)
Pages (from-to)4584-4587
Number of pages4
JournalBlood
Volume110
Issue number13
DOIs
StatePublished - Dec 15 2007

Fingerprint

Transplantation (surgical)
Transplants
Pediatrics
Homologous Transplantation
Graft vs Host Disease
Granulocyte Colony-Stimulating Factor
Stem cells
Bone Marrow Transplantation
Grafts
Bone
Blood
Stem Cells
Bone Marrow
Prospective Studies
Tissue Donors
Platelets
Multicenter Studies
Disease-Free Survival
Neutrophils
Blood Platelets

ASJC Scopus subject areas

  • Hematology

Cite this

A prospective study of G-CSF-primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children : A Pediatric Blood and Marrow Transplant Consortium (PBMTC) study. / Frangoul, Haydar; Nemecek, Eneida; Billheimer, Dean; Pulsipher, Michael A.; Khan, Shakila; Woolfrey, Ann; Manes, Becky; Cole, Catherine; Walters, Mark C.; Ayas, Mouhab; Ravindranath, Yaddanapudi; Levine, John E.; Grupp, Stephan A.

In: Blood, Vol. 110, No. 13, 15.12.2007, p. 4584-4587.

Research output: Contribution to journalArticle

Frangoul, H, Nemecek, E, Billheimer, D, Pulsipher, MA, Khan, S, Woolfrey, A, Manes, B, Cole, C, Walters, MC, Ayas, M, Ravindranath, Y, Levine, JE & Grupp, SA 2007, 'A prospective study of G-CSF-primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: A Pediatric Blood and Marrow Transplant Consortium (PBMTC) study', Blood, vol. 110, no. 13, pp. 4584-4587. https://doi.org/10.1182/blood-2007-07-101071
Frangoul, Haydar ; Nemecek, Eneida ; Billheimer, Dean ; Pulsipher, Michael A. ; Khan, Shakila ; Woolfrey, Ann ; Manes, Becky ; Cole, Catherine ; Walters, Mark C. ; Ayas, Mouhab ; Ravindranath, Yaddanapudi ; Levine, John E. ; Grupp, Stephan A. / A prospective study of G-CSF-primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children : A Pediatric Blood and Marrow Transplant Consortium (PBMTC) study. In: Blood. 2007 ; Vol. 110, No. 13. pp. 4584-4587.
@article{912865fa955c469ebd5d3c3af0abc2ab,
title = "A prospective study of G-CSF-primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: A Pediatric Blood and Marrow Transplant Consortium (PBMTC) study",
abstract = "A prospective multicenter trial was conducted to evaluate the safety and feasibility of granulocyte colony-stimulating factor (G-CSF)-primed bone marrow (G-BM) in children receiving allogeneic bone marrow transplantation (BMT). A total of 42 children with a median age of 9.8 years (range, 0.8-17 years) were enrolled. Donors with median age of 9.2 years (range, 1.1-22 years) received 5 μg/kg per day of subcutaneous G-CSF for 5 consecutive days. BM was harvested on the fifth day. No donor experienced complications related to G-CSF administration or marrow harvest. Median nucleated (NC) and CD34 cells infused was 6.7 × 108/kg (range, 2.4-18.5 × 108/kg) and 7.4 × 106/kg (range, 2-27.6 × 106/kg), respectively. Neutrophil and platelet engraftment was at a median of 19 days (range, 13-28 days) and 20 days (range, 9-44 days), respectively. A total of 13 (32{\%}) patients developed grade 2 graft-versus-host disease (GVHD), and 5 (13{\%}) of 40 evaluable patients developed chronic GVHD (3 limited and 2 extensive). Higher cell dose was not associated with increased risk of acute or chronic GVHD. Overall survival and event-free survival at 2 years were 81{\%} and 69{\%}, respectively. Collection of G-BM from pediatric donors is safe, and can result in high NC and CD34 cell doses that facilitate engraftment after myeloablative BMT without a discernable increase in the risk of GVHD.",
author = "Haydar Frangoul and Eneida Nemecek and Dean Billheimer and Pulsipher, {Michael A.} and Shakila Khan and Ann Woolfrey and Becky Manes and Catherine Cole and Walters, {Mark C.} and Mouhab Ayas and Yaddanapudi Ravindranath and Levine, {John E.} and Grupp, {Stephan A.}",
year = "2007",
month = "12",
day = "15",
doi = "10.1182/blood-2007-07-101071",
language = "English (US)",
volume = "110",
pages = "4584--4587",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

TY - JOUR

T1 - A prospective study of G-CSF-primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children

T2 - A Pediatric Blood and Marrow Transplant Consortium (PBMTC) study

AU - Frangoul, Haydar

AU - Nemecek, Eneida

AU - Billheimer, Dean

AU - Pulsipher, Michael A.

AU - Khan, Shakila

AU - Woolfrey, Ann

AU - Manes, Becky

AU - Cole, Catherine

AU - Walters, Mark C.

AU - Ayas, Mouhab

AU - Ravindranath, Yaddanapudi

AU - Levine, John E.

AU - Grupp, Stephan A.

PY - 2007/12/15

Y1 - 2007/12/15

N2 - A prospective multicenter trial was conducted to evaluate the safety and feasibility of granulocyte colony-stimulating factor (G-CSF)-primed bone marrow (G-BM) in children receiving allogeneic bone marrow transplantation (BMT). A total of 42 children with a median age of 9.8 years (range, 0.8-17 years) were enrolled. Donors with median age of 9.2 years (range, 1.1-22 years) received 5 μg/kg per day of subcutaneous G-CSF for 5 consecutive days. BM was harvested on the fifth day. No donor experienced complications related to G-CSF administration or marrow harvest. Median nucleated (NC) and CD34 cells infused was 6.7 × 108/kg (range, 2.4-18.5 × 108/kg) and 7.4 × 106/kg (range, 2-27.6 × 106/kg), respectively. Neutrophil and platelet engraftment was at a median of 19 days (range, 13-28 days) and 20 days (range, 9-44 days), respectively. A total of 13 (32%) patients developed grade 2 graft-versus-host disease (GVHD), and 5 (13%) of 40 evaluable patients developed chronic GVHD (3 limited and 2 extensive). Higher cell dose was not associated with increased risk of acute or chronic GVHD. Overall survival and event-free survival at 2 years were 81% and 69%, respectively. Collection of G-BM from pediatric donors is safe, and can result in high NC and CD34 cell doses that facilitate engraftment after myeloablative BMT without a discernable increase in the risk of GVHD.

AB - A prospective multicenter trial was conducted to evaluate the safety and feasibility of granulocyte colony-stimulating factor (G-CSF)-primed bone marrow (G-BM) in children receiving allogeneic bone marrow transplantation (BMT). A total of 42 children with a median age of 9.8 years (range, 0.8-17 years) were enrolled. Donors with median age of 9.2 years (range, 1.1-22 years) received 5 μg/kg per day of subcutaneous G-CSF for 5 consecutive days. BM was harvested on the fifth day. No donor experienced complications related to G-CSF administration or marrow harvest. Median nucleated (NC) and CD34 cells infused was 6.7 × 108/kg (range, 2.4-18.5 × 108/kg) and 7.4 × 106/kg (range, 2-27.6 × 106/kg), respectively. Neutrophil and platelet engraftment was at a median of 19 days (range, 13-28 days) and 20 days (range, 9-44 days), respectively. A total of 13 (32%) patients developed grade 2 graft-versus-host disease (GVHD), and 5 (13%) of 40 evaluable patients developed chronic GVHD (3 limited and 2 extensive). Higher cell dose was not associated with increased risk of acute or chronic GVHD. Overall survival and event-free survival at 2 years were 81% and 69%, respectively. Collection of G-BM from pediatric donors is safe, and can result in high NC and CD34 cell doses that facilitate engraftment after myeloablative BMT without a discernable increase in the risk of GVHD.

UR - http://www.scopus.com/inward/record.url?scp=39649088491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39649088491&partnerID=8YFLogxK

U2 - 10.1182/blood-2007-07-101071

DO - 10.1182/blood-2007-07-101071

M3 - Article

C2 - 17827386

AN - SCOPUS:39649088491

VL - 110

SP - 4584

EP - 4587

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -